A detailed history of First Horizon Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 1,572 shares of CRSP stock, worth $81,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,572
Previous 1,436 9.47%
Holding current value
$81,555
Previous $97,000 13.4%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$51.17 - $68.18 $6,959 - $9,272
136 Added 9.47%
1,572 $84,000
Q1 2024

Apr 26, 2024

BUY
$60.67 - $89.12 $485 - $712
8 Added 0.56%
1,436 $97,000
Q4 2023

Feb 06, 2024

SELL
$38.62 - $72.18 $4,904 - $9,166
-127 Reduced 8.17%
1,428 $89,000
Q3 2023

Oct 27, 2023

SELL
$45.39 - $59.0 $24,601 - $31,978
-542 Reduced 25.85%
1,555 $70,000
Q2 2023

Aug 03, 2023

SELL
$43.47 - $67.77 $24,951 - $38,899
-574 Reduced 21.49%
2,097 $117,000
Q1 2023

May 15, 2023

BUY
$41.0 - $56.12 $21,033 - $28,789
513 Added 23.77%
2,671 $120,000
Q4 2022

Feb 10, 2023

SELL
$39.19 - $65.67 $11,247 - $18,847
-287 Reduced 11.74%
2,158 $87,000
Q3 2022

Nov 09, 2022

SELL
$61.1 - $83.78 $33,177 - $45,492
-543 Reduced 18.17%
2,445 $159,000
Q2 2022

Aug 02, 2022

BUY
$43.23 - $73.83 $129,171 - $220,604
2,988 New
2,988 $181,000
Q1 2022

May 10, 2022

SELL
$53.19 - $79.24 $52,445 - $78,130
-986 Closed
0 $0
Q4 2021

Feb 09, 2022

BUY
$70.09 - $111.29 $13,317 - $21,145
190 Added 23.87%
986 $74,000
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $53,887 - $76,596
489 Added 159.28%
796 $89,000
Q3 2021

Nov 09, 2021

SELL
$110.2 - $156.64 $30,194 - $42,919
-274 Reduced 47.16%
307 $34,000
Q2 2021

Aug 09, 2021

BUY
$100.84 - $161.89 $16,033 - $25,740
159 Added 37.68%
581 $94,000
Q1 2021

May 11, 2021

BUY
$110.72 - $210.04 $46,723 - $88,636
422 New
422 $51,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.05B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.